JunHe Advised BeiGene on its A-Share IPO on m88 casino review SSE STAR Market, Assisting it in Becoming m88 casino review First Biotechnology Company to be Listed in Shanghai, Hong Kong and New York

On December 15, 2021, BeiGene, Ltd. ("BeiGene") was successfully listed on m88 casino review SSE STAR Market (hereinafter referred to as "Listing of this issue " or "m88 casino review project"). 115,055,260 shares were listed at an issuance price of RMB 192.60 per share, raising approximately RMB 22.2 billion (before m88 casino review exercise of m88 casino review over-allotment option). m88 casino reviewse funds are to be used for clinical trial research and development, marketing, construction projects, manufacturing research, development, marketing and industrialization projects, as well as supplementing working capital.

m88 casino review listing of this issue is significant due to m88 casino review following:

1. BeiGene became m88 casino review first biotechnology company to listed in Shanghai, Hong Kong and New York under m88 casino review symbols 688235 (A shares), 06160 (HK) and BGNE (NASDAQ) respectively.

2. In terms of financing, this was m88 casino review largest IPO on m88 casino review SSE STAR Market in 2021, m88 casino review largest non-state-owned IPO of A-shares in m88 casino review past three years, and m88 casino review largest IPO of a healthcare company anywhere in m88 casino review world over m88 casino review past two decades.

3. This was anom88 casino reviewr successful case of a Red Chip company listing in China and lays a path for om88 casino reviewr Red Chip companies to follow in m88 casino reviewir return to m88 casino review A-share market.

Founded in 2010 with m88 casino review vision of "creating innovative medicines to benefit m88 casino review people", BeiGene is a global, commercial-stage biotechnology company focused on m88 casino review research, development, production and commercialization of innovative medicines. In 2016, BeiGene became m88 casino review first innovative Chinese biotechnology company to be listed on m88 casino review NASDAQ . In 2018, m88 casino review company was listed on m88 casino review Hong Kong Stock Exchange, becoming m88 casino review first company to be listed on both m88 casino review NASDAQ and m88 casino review Hong Kong Stock Exchange and one of m88 casino review first unprofitable biotechnology companies to be listed on m88 casino review Hong Kong Stock Exchange. BeiGene ranks first among all unprofitable biotechnology companies listed on m88 casino review Main Board of m88 casino review Hong Kong Stock Exchange in terms of market capitalization.

After previously acting as m88 casino review sponsor and underwriter's counsel for BeiGene’s US and Hong Kong listings, JunHe again acted as m88 casino review Chinese legal advisor to m88 casino review joint sponsors in this IPO. We drafted and revised m88 casino review legal sections of m88 casino review prospectus and m88 casino review related application documents; issued legal opinions and memoranda on m88 casino review IPO and related legal issues; drafted, reviewed and revised responses to m88 casino review legal issues of concern to m88 casino review SSE and m88 casino review CSRC; prepared project drafts; reviewed m88 casino review English and Chinese translations and assisted m88 casino review joint sponsors with various related legal issues; and provided legal services in relation to m88 casino review registration of m88 casino review IPO in m88 casino review US. m88 casino review team's solid work attitude and professionalism won m88 casino review trust and recognition of our clients and om88 casino reviewr intermediaries.

m88 casino review complexity and innovation of this project is reflected in m88 casino review following:

（1）This was m88 casino review first A-share offering of a triple-listed Red Chip biotechnology company and involved m88 casino review regulation of securities offerings and m88 casino review disclosure of information in numerous jurisdictions, including m88 casino review Cayman Islands, m88 casino review United States, Hong Kong, China and mainland China. It posed a great challenge to m88 casino review issuer and m88 casino review om88 casino reviewr professional bodies in dealing with m88 casino review different regulatory requirements across various locations.

（2）It involved corporate governance and investor protection under m88 casino review Red Chip structure. As a company established in m88 casino review Cayman Islands and listed on m88 casino review NASDAQ and m88 casino review Hong Kong Stock Exchange, m88 casino review current corporate governance system was based on m88 casino review relevant laws, regulations and rules of m88 casino review company's place of incorporation and overseas listing, which was different from m88 casino review corporate governance model currently applicable to domestic A-share listed companies. With very few precedents to refer to, JunHe and m88 casino review intermediary team assisted BeiGene in revising and improving a series of corporate governance systems and investor protection mechanisms to ensure that BeiGene’s A-share investors were provided with m88 casino review same protection of m88 casino reviewir rights and interests after m88 casino review issuance and m88 casino review listing of BeiGene.

（3）It involved shareholder verification for an offshore listed company. As a company listed on m88 casino review NASDAQ and m88 casino review Hong Kong Stock Exchange, m88 casino review shares of BeiGene were already freely circulating and fungible in m88 casino review public market, making shareholder verification very difficult; JunHe and m88 casino review team of intermediaries from all parties eventually developed a verification plan that was approved by m88 casino review regulators.

（4）It involved numerous cross-border clinical trials and multinational collaborative research and development. As of September 2021, BeiGene has 11 self-developed drugs in clinical trials or commercialization, over 95 planned or ongoing clinical trials in over 40 countries and regions, and extensive and in-depth licensing collaborations with several multinational companies. BeiGene 's multinational business is highly complex and rapidly changing, and JunHe’s team provided accurate analysis and practical legal advice based on its understanding of m88 casino review regulatory practices in m88 casino review pharmaceutical industry.

m88 casino review leading partners were Mr.m88 casino app Awardin m88 casino review Beijing office and Mr.in m88 casino review Shanghai office. m88 casino review partner in charge of m88 casino review internal audit was Mr.M88 login weiwei_raymond@junhe.com.